Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo

NCT ID: NCT02217033

Last Updated: 2017-04-18

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2016-04-30

Brief Summary

The purpose of this study is to evaluate the effects of consuming "R" on quality of life in the areas of insomnia, fatigue, and depression in female breast cancer patients receiving multi-cycle adjuvant chemotherapy.

Detailed Description

Female breast cancer patients eligible for adjuvant therapy with four cycles of Taxotere and Cytoxan chemotherapy after surgery will be enrolled for the study.

Eligible subjects will begin to consume either "R" or purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume either "R" or placebo through Cycle 1, Cycle 2, Cycle 3, Cycle 4, and for an additional 12 weeks after completing chemotherapy.

Study procedures will include clinical lab assessments, analysis of inflammatory markers, RNA biomarkers, adverse events, subject diary, and quality of life measurements for insomnia, fatigue and depression.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: QUADRUPLE

Study Groups

Purified Water

In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.

Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days.

Group Type: PLACEBO_COMPARATOR

Placebo (water)

Intervention Type: OTHER

'R' (Electro-kinetically altered beverage)

Patients randomized to this arm will begin to consume "R" (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.

Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days.

Group Type: EXPERIMENTAL

'R' (Electro-kinetically altered beverage)

Intervention Type: OTHER

Interventions

'R' (Electro-kinetically altered beverage)

Intervention Type: OTHER

Placebo (water)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Female, non-smokers ≥ 18 years of age
• Histologically or cytologically confirmed diagnosis of Stage I or II adenocarcinoma of the breast and a candidate for adjuvant chemotherapy
• Scheduled to receive 4 cycles of adjuvant Taxotere and Cytoxan chemotherapy (TC): docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on Day 1 of each 21-day cycle
• Eastern Cooperative Oncology Group Status (ECOG) performance status of ≤ 1
• No prior treatment for breast cancer other than surgery
• Adequate baseline organ function as evidenced by:

• Hemoglobin ≥ 9 g/dL
• Absolute neutrophil count ≥ 1.5 x 109 cells/mm3
• Platelet count ≥ 100,000 cells/mm3
• Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
• Alkaline phosphatase ≤ 1.5 x ULN
• No history of other malignancies within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma or squamous cell carcinoma of the skin that have been previously treated with curative intent
• Women of childbearing potential who commit to using two forms of highly effective non-hormonal contraception either by the subject and/or partner during the study
• Negative urine pregnancy test at screening
• Negative urine drug screen (UDS) for drugs of abuse including cotinine (nicotine) at screening
• Subjects must be capable of understanding the purpose and risks of the study and provide written, voluntary informed consent

Exclusion Criteria

• Preexisting diagnosed psychiatric disorder as defined by The Diagnostic and Statistical Manual (DSM) of Mental Disorders (published by the American Psychiatric Association). Subjects with a diagnosis of depression will be allowed to enter into study as long as they have been treated with medication for ≥ 6 months and/or depression is considered to be well controlled
• Pregnant or lactating
• Diabetes
• Concomitant use of any sleeping agents during the course of the study (Anti- anxiety medications will be allowed)
• Steroid therapy other than the standard prescribed therapy of either of the following during the course of the study:

• Dexamethasone 4-12 mg IV on Day 1 of any cycle
• Dexamethasone 4-12 mg PO on Day 2 and Day 3 of any cycle
• Anti-estrogen therapy other than the standard prescribed therapy of one of the following:

• Tamoxifen/Nolvadex 20 mg PO daily
• Anastrazole/Arimidex 1 mg PO daily
• Letrozole/Femara 2.5 mg PO daily
• Exemestane/Aromasin 25 mg PO daily
• Use of any other antiemetic regimen other than the following (with the exception of PO antiemetics):

• Emend /Aprepitant150 mg IV on Day 1 of any cycle
• Aloxi/Palonosetron 0.25 mg IV on Day 1 of any cycle
• Dexamethasone 8 mg IV on Day 1 of any cycle
• Dexamethasone 8 mg PO on Day 2 and Day 3 of any cycle
• Zofran/Ondansetron 12 mg IV on Day 1 of any cycle
• Kytrile/Granisetron 1-2 mg IV on Day 1 of any cycle
• Therapy with any immunomodulatory or immunosuppressive drugs within 6 months prior to enrollment
• Known history of positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody
• Any change in the initially prescribed chemotherapy
• Use of herbal remedies, dietary supplements or mega-vitamins, with the exception of a multi-vitamin
• Investigator deems the subject to be unable or unwilling to comply with the requirements of the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

South Sound Care Foundation

OTHER

Sponsor Role: lead

Responsible Party

Francis (Frank) Senecal, MD

Site Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Francis (Frank) Senecal, MD

Role: PRINCIPAL_INVESTIGATOR

Northwest Medical Specialties

Locations

NWMS Bonney Lake - Medical Oncology

Bonney Lake, Washington, United States

NWMS Federal Way - Medical Oncology

Federal Way, Washington, United States

NWMS Gig Harbor - Medical Oncology

Gig Harbor, Washington, United States

NWMS Lakewood - Medical Oncology

Lakewood, Washington, United States

Rainier Hematology-Oncology, WA

Puyallup, Washington, United States

NWMS Tacoma - Medical Oncology & Infectious Diseases

Tacoma, Washington, United States

Countries

United States

Other Identifiers

R822662

Identifier Type: -

Identifier Source: org_study_id